Key Market Indicators
Sales of Slovene antirheumatic medicine are expected to reach around $9.25 million by 2026. This is a slight decrease from the 2021 figure of $9.9 million. Since 2012, sales have risen on average by 0.8% per year. In 2021, Slovenia was ranked 22nd for antirheumatic medicine sales, just behind Estonia, which generated $9.9 million. Germany, Spain, and Canada ranked second, third, and fourth respectively.
